Exposed Bone After Extraction on Denosumab
Mrs. T is a 70-year-old woman with metastatic breast cancer receiving denosumab 120 mg subcutaneously monthly and letrozole. She received intravenous zoledronic acid for 2 years before that. Four months ago, teeth #19 and #20 were extracted because of caries. She now has a 1.2 cm area of exposed bone in the right posterior mandible. It is not painful, there is no pus or fistula, and there is only mild surrounding erythema. She takes calcium and vitamin D and has no diabetes. Her oncologist plans to start a new chemotherapy regimen. She asks whether she should stop denosumab and whether hyperbaric oxygen will cure the exposed bone.
1. What is the diagnosis and AAOMS stage? What clinical or radiographic features would change the stage?
Read the worked answer
Medication-related osteonecrosis of the jaw (MRONJ), stage 1. She has exposed bone for more than 8 weeks in a patient with a history of antiresorptive therapy (denosumab and prior zoledronic acid) and no signs of infection. Stage 1 is exposed bone without pain, erythema, pus, or fistula. Stage 2 would require infection, such as pain, erythema, purulent drainage, or fistula. Stage 3 would require extensive involvement, pathologic fracture, extraoral fistula, or osteolysis extending to the inferior border. Stage 0 is no exposed bone but nonspecific symptoms.
Her mild erythema is not enough for stage 2 without pain or drainage. Confirm with imaging such as CBCT or panoramic radiograph to assess sequestrum and rule out fracture. Document the size and location.
2. Outline your local and systemic management now, including whether antibiotics or surgery are indicated.
Read the worked answer
Conservative management: chlorhexidine 0.12% rinse twice daily, gentle saline rinses, and removal of loose sequestra only. Do not perform aggressive debridement or resection at stage 1. No antibiotics are indicated without infection. Provide analgesia if needed and nutritional support. Review every 2–3 months.
If she develops pain, swelling, or drainage indicating stage 2, start antibiotics with anaerobic coverage - amoxicillin/clavulanate 875/125 mg twice daily, or clindamycin 300 mg four times daily if penicillin-allergic - and consider superficial debridement. Hyperbaric oxygen is not first-line and has not been shown to reliably improve stage 1 disease. Avoid ill-fitting dentures and trauma. Coordinate with her oncologist before any procedure.
3. How would you advise her about drug holiday and future dental care? Include the evidence and the role of the oncologist.
Read the worked answer
Denosumab is not incorporated into bone and its effect wanes after stopping, but a drug holiday has not been proven to improve MRONJ healing and may increase fracture or skeletal-related event risk. The decision belongs to the oncologist, who must weigh cancer control against the low likelihood of benefit. For future extractions, do not stop denosumab routinely before surgery; instead, perform atraumatic extraction with primary closure and preoperative chlorhexidine.
Prevention is key: optimize oral health before starting antiresorptives, avoid elective extractions if possible, and use removable prostheses carefully. If she needs a future extraction, coordinate with oncology and document the risk. There is no role for a fixed-duration drug holiday in guidelines. Hyperbaric oxygen may be considered as an adjunct in refractory cases, not as primary therapy.